Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Amicus Therapeutics Inc. buy UBS Group AG

Start price
€12.00
02.03.23 / 50%
Target price
€16.05
02.03.24
Performance (%)
0.83%
End price
€12.10
03.03.24
Summary
This prediction ended on 03.03.24 with a price of €12.10. During the runtime of the prediction for Amicus Therapeutics Inc. the price only changed by 0.83%. UBS_Group_AG has a follow-up prediction for Amicus Therapeutics Inc. where he still thinks Amicus Therapeutics Inc. is a Buy. UBS_Group_AG has 50% into this prediction
Performance without dividends (%)
Name 1w 1m 1y
Amicus Therapeutics Inc. - - -
iShares Core DAX® 1.395% -0.696% 15.472%
iShares Nasdaq 100 2.287% 7.501% 34.748%
iShares Nikkei 225® 1.617% 2.769% 11.442%
iShares S&P 500 0.659% 4.280% 26.778%

Comments by UBS_Group_AG for this prediction

In the thread Amicus Therapeutics Inc. diskutieren
Prediction Buy
Perf. (%) 0.83%
Target price 16.051
Change
Ends at 02.03.24

Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its price target raised by analysts at UBS Group AG from $15.00 to $17.00. They now have a "buy" rating on the stock.
Ratings data for FOLD provided by MarketBeat

In the thread Trading Amicus Therapeutics Inc.
Prediction Buy
Perf. (%) 0.83%
Target price 16.051
Change
Ends at 02.03.24

Die von UBS_Group_AG gewählte maximale Laufzeit wurde überschritten

Current prediction by UBS_Group_AG for Amicus Therapeutics Inc.

buy
Amicus Therapeutics Inc.

Start price
Target price
Perf. (%)
€8.60
10.05.24
€17.63
10.05.25
6.40%
20.06.24